Eris Lifesciences Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of ERIS Lifesciences Ltd is ₹ 1340 as of 18 May 15:30 . The P/E Ratio of ERIS Lifesciences Ltd changed from 23.1 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 18.86% over 5 yearsThe P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 45 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of ERIS Lifesciences Ltd changed from ₹ 8207 crore on March 2021 to ₹ 19287 crore on March 2025 . This represents a CAGR of 18.64% over 5 yearsThe Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 2637 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of ERIS Lifesciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 807.59 crore. This represent the decline of -100% The revenue of Senores Pharmaceuticals Ltd for the Mar '26 is ₹ 192.86 crore as compare to the Dec '25 revenue of ₹ 178.34 crore. This represent the growth of 8.14% The ebitda of ERIS Lifesciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 264.51 crore. This represent the decline of -100% The ebitda of Senores Pharmaceuticals Ltd for the Mar '26 is ₹ 65.16 crore as compare to the Dec '25 ebitda of ₹ 57.79 crore. This represent the growth of 12.75% The net profit of ERIS Lifesciences Ltd changed from ₹ 89.55 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 10.91 crore to ₹ 36.67 crore over 8 quarters. This represents a CAGR of 83.33% The Dividend Payout of ERIS Lifesciences Ltd changed from 21.3 % on March 2021 to 129.35 % on March 2025 . This represents a CAGR of 43.44% over 5 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated on January 25, 2007.
Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective.

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

FAQs for the comparison of ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, ERIS Lifesciences Ltd or Senores Pharmaceuticals Ltd?

Market cap of ERIS Lifesciences Ltd is 19,038 Cr while Market cap of Senores Pharmaceuticals Ltd is 4,846 Cr

What are the key factors driving the stock performance of ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd?

The stock performance of ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd?

As of May 18, 2026, the ERIS Lifesciences Ltd stock price is INR ₹1373.95. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹1052.35.

How do dividend payouts of ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of ERIS Lifesciences Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.